Victoria N. Pyliv
ORCID:
0000-0003-0475-0872
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- PI3K/AKT/mTOR signaling in cancer
York District Hospital
2022
Tatyana N. Sokolova
Tatyana I. Solov'eva
Svetlana N. Aleksakhina
M. B. Bolieva
V. Е. Goldberg
and 79
more
Marianna V. Kibisheva
К. V. Menshikov
Dmitrii V. Ryazanov
Aleksandr V. Shkradyuk
Yana Chapko
Anna A. Shchukina
Idris M. Khabriev
Dmitrii V. Kirtbaya
Alexey M. Degtyarev
Aleksandr A. Epkhiev
Yana A. Tyugina
Aleksandr V. Togo
Mirza A. Murachuev
Aglaya G. Ievleva
Evgenii N. Imyanitov
A. A. Grechkina
Alena S. Stel'makh
Svetlana V. Odintsova
Grigorii A. Janus
Khedi S. Musaeva
V. L. Chang
A. V. Fateeva
Ekaterina P. Startseva
Н. О. Попова
Yulia Vsevolodovna Mikheeva
Anna Vasilevskaya
Victoria S. Barbara
Petimat I. Khabibulaeva
Alina Khlobystina
Ludmila V. Bembeeva
Vladimir I. Vladimirov
Oleg L. Petrenko
Natalia G. Ruskova
Ekaterina L. Serikova
Ksenia S. Subbotina
Svetlana A. Tkachenko
D. Yu. Yukalchuk
Elena Basova
M Stepanova
Sanal P. Erdniev
А. Yu. Goryainova
M. I. Gluzman
Р. В. Орлова
Anastasiya I. Stukan
Р. А. Зуков
Alena V. Zyuzyukina
Yulia N. Murunova
А. В. Султанбаев
Elena N. Vorobeva
Leonid M. Mikhaevich
Anna N. Lysenko
Z. K. Khachmamuk
Andrey E. Kozlov
S. Yu. Bakharev
Victoria N. Pyliv
Irina K. Amirkhanova
Shahen G. Parsyan
Elena I. Rossokha
Leri D. Osidze
Irina S. Shumskaya
A. V. Agaeva
Tatiana A. Kasmynina
Veronika V. Klimenko
Kamila T. Akhmetgareeva
A. A. Vakhitova
Madina D. Chakhkieva
Yana A. Udalova
В. Н. Дмитриев
Yana I. Bakshun
Alexey E. Vasilyev
Gasimly Dunya D
Nadezhda A. Kravchenko
Dmitriy A. Maksimov
Alfia I. Nesterova
Zaur M. Khamgokov
Ineza O. Sharvashidze
Christina H. Gadzaova
Galina G. Rakhmankulova
Kseniya A. Shvaiko
Background. By 2020, breast cancer (BC) has become the most frequent malignancy in world. The common type of BC is HR+/HER2-negative cancer,2540% which harbors PIK3CA mutations that affect catalytic subunit PI3K protein. alterations are actionable, as such neoplasms can be treated with a combination fulvestrant and inhibitor alpelisib. As have an extremely versatile effect on characteristics tumor cell, numerous associations various clinico-pathological traced.
 Aim. Our aim was to...
10.26442/8151434.2022.1.201435
article
EN
Journal of Modern Oncology
2022-04-30
Coming Soon ...